

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet

1

of

1

**Complete if Known**

Application Number	09/234,532
Filing Date	01/21/1999
First Named Inventor	Alfred Sapse
Art Unit	1623
Examiner Name	Howard V. Owens Jr.
Attorney Docket Number	02022097

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> <i>(if known)</i>				

Examiner  
Signature

Harvard Univ

Date \_\_\_\_\_


**Considered**

11-6-03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/234,532
Filing Date	01/21/1999
First Named Inventor	Alfred Sapse
Art Unit	1623
Examiner Name	Howard V. Owens Jr.
Attorney Docket Number	02022097

Sheet 1 of 1**NON PATENT LITERATURE DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	14	<del>U.S. Trademark Registration No. 2176048 for ANTICORT, <a href="http://tess2.uspto.gov/bin/showfield?f=doc&amp;state=k1k9kv.2.1">tess2.uspto.gov/bin/showfield?f=doc&amp;state=k1k9kv.2.1</a></del>	
<i>HO</i>	15	"Study Supports Role of Anticort in Treating Alzheimer's, HIV," P/S/L/Group (1998), <a href="http://www.pslgroup.com/dg/6de2.htm">www.pslgroup.com/dg/6de2.htm</a>	

Examiner  
Signature*Howard V. Owens Jr.*Date  
Considered*11-6-03*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/234,532
				Filing Date	01/21/1999
				First Named Inventor	Alfred Sapse
				Art Unit	1623
				Examiner Name	Howard V. Owens Jr.
Sheet	1	of	2	Attorney Docket Number	02022097

RECEIVED  
SEP 11 2003  
TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Ho	4/1	BRANADAO-NETO, ET AL. "Zinc Acutely and Temporativity Inhibits Adrenal Cortisol Secretion in Humans," Biological Trace Element Research, 24, 83-89 (1990),	
Ho	5/1	FACCKELMANN. "The Cortisol Connection: Does a Stress Hormone Play a Role in Aids?" ScienceNewsOnline (1997), www.sciencenews.org/sn_arc97/11_29_97/bob1.htm.	
Ho	6/1	SAPSE. "Stress, Cortisol, Interferon and "Stress" Diseases," Medical Yypotheses, 13, 31-44 (1984),	
Ho	7/1	"Findings Show Coritsol's Major Role in Aids and Other Diseases," P/S/L/Group (1996), www.pslgroup.com/dg/9AC6.htm.	
Ho	8/1	SAPSE. "Cotisol, High Cortisol Diseases and Anti-Cortisol Theratpy", Psychoneruoendrocinolgy, 22 Suppl 1, S3-S10 (1997),	
Ho	9/1	KLING, ET AL. "Neuroendocrine Effects of Limbic Activation by Electrical, Spontantous, and Pharmacological Modes: Relevance to the Pathophysiology of Affective Dysregulation in Psychiatric Disorders", Prog. Neuro-Psychopharamcol. & Biol. Psyciat., 11, 459-481 (1987),	
Ho	10/1	KELLNER, ET AL. "Intravenous Procaine as a Probe of Limbic System Activity in Psychiatric Patients and Normal Controls," Biol Psychiatry, 22, 9, 1107-1126 (1987),	
Ho	11/1	"IND Filed with FDA for New ANTICORT AIDS Treatment," P/S/L/Group (1997), www.pslgroup.com/dg/9E4E2.htm.	
Ho	12/1	"Clinical Trial Update: STGI Announces Anticourt's FDA Phase I/II is Moving Forward," Business Wire (1999), www.aegis.com/news/bw/BW990715.html.	
Ho	13/1	"Samaritan Pharmaceuticals, Inc.- Anticourt," Samaritan Pharmaceuticals (2001), www.samaritanpharma.com/?m=10&p=8	

Examiner Signature	<i>Howard Owens</i>	Date Considered	11-6-03
--------------------	---------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.